Cantor Fitzgerald’s Nephros NEPH Stock Holding History

Cantor Fitzgerald’s Portfolio NEPH Stock Details NEPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-12,813	Closed	-$56K	–	833
2022 Q1	$56K	Buy	+12,813	New	+$60.8K	﹤0.01%	328

Other funds holding NEPH

Bard Associates Chicago, Illinois $451M AUM 66.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

CPA

Cowen Prime Advisors New York $290M AUM 57.8% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Elkhorn Partners Omaha, Nebraska $117M AUM 28.12% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Cantor Fitzgerald's NEPH Position: Q2 2022 in Review

Cantor Fitzgerald sold out of Nephros (NEPH) in Q2 2022, closing a stake of 12,813 shares — an estimated $56K sold.

Cantor Fitzgerald first reported a position in NEPH in Q1 2022 and held it in 1 quarter. The position peaked at $56K in Q1 2022. 17 funds tracked by Wall St. Rank hold NEPH as of Q2 2022.

Cantor Fitzgerald reported no remaining Nephros position as of Q2 2022 after selling out during the quarter.
Cantor Fitzgerald sold 12,813 Nephros shares in Q2 2022, an estimated $56K.
Cantor Fitzgerald first reported a position in Nephros in Q1 2022 and held it in 1 quarter.
Cantor Fitzgerald's Nephros position peaked at $56K in Q1 2022.
17 funds tracked by Wall St. Rank held Nephros as of Q2 2022.

Based on Cantor Fitzgerald's 13F filing for Q2 2022, filed 15 Aug 2022.